Specify a stock or a cryptocurrency in the search bar to get a summary
Biomerica Inc
BMRABiomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California. Address: 17571 Von Karman Avenue, Irvine, CA, United States, 92614
Analytics
WallStreet Target Price
13 USDP/E ratio
–Dividend Yield
1.52 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures BMRA
Dividend Analytics BMRA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History BMRA
Stock Valuation BMRA
Financials BMRA
Results | 2019 | Dynamics |